The favorable toxicology results de-risk the NMRA-215 program and support the IND timeline. Traders should monitor for the IND submission in Q4 2026 and subsequent Phase 1 initiation, which could drive further upside if clinical data is positive. Given the company's small market cap (~$276M), positive pipeline news may have outsized impact.
Drug in focus
NMRA drug pipeline →NMRA-215
● Neutral Named in this 8-K- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 27 $1.66entry
- T+1 · 4mo ago +1.20%α +0.97% · $1.68
- T+5 · 4mo ago −3.01%α −4.09% · $1.61
- T+20 · 3mo ago −8.13%α −11.43% · $1.53
- T+60 · 28d ago −71.69%α −75.39% · $0.4700
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor in development for obesity and cardiometabolic disease. A repeat 13-week rat study found no unexpected adverse findings, clearing a key safety concern and enabling the company to plan an IND submission in Q4 2026 with a Phase 1 study by end of 2026. This removes a significant pipeline risk and supports advancement toward the clinic.
Key Facts
- Repeat 13-week rat toxicology study (162 animals) showed no unexpected in-life adverse findings, resolving concerns from a prior study where 5 of 142 animals had adverse events.
- Company opened a for-cause audit of the prior study, which revealed discrepancies; management believes prior findings were not related to NMRA-215.
- Plans to submit an IND for NMRA-215 in Q4 2026 and initiate a Phase 1 study by the end of 2026.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disease with pre-clinical data showing class-leading weight loss and additive effects with semaglutide.
Financial Impact
No financial data provided; the event is a pre-clinical pipeline milestone with no revenue impact. Positive catalyst for stock valuation but no direct financial figures.
Risk Factors
- Pre-clinical data may not translate to clinical success; NMRA-215 still faces Phase 1 safety and efficacy hurdles.
- Competition from other NLRP3 inhibitors and obesity treatments (e.g., incretins) could limit commercial potential.
- Company is pre-revenue with no financial data provided; cash runway and need for future financing are not addressed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-316819 |
| Document: nmra-ex99_1.htm | 0001193125-26-316819 |
| Document: 0001193125-26-316819-index-headers.html | 0001193125-26-316819 |
| Document: 0001193125-26-316819-index.html | 0001193125-26-316819 |
| Document: 0001193125-26-316819.txt | 0001193125-26-316819 |
Track record
14 reports on NMRA
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Viewing Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers